SEC Info - Aveanna Healthcare Holdings, Inc. - ‘10-Q’ for 4/2/22

SEC Info℠

Home

Help

Please Sign In

Aveanna Healthcare Holdings, Inc. – ‘10-Q’ for 4/2/22 – ‘EX-31.1’

On: Wednesday, 5/11/22, at 4:17pm ET · For: 4/2/22 · Accession #: 950170-22-9347 · File #: 1-40362

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/11/22  Aveanna Healthcare Holdings, Inc. 10-Q        4/02/22   63:7.1M                                   Donnelley … Solutions/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    744K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
11: R1          Document and Entity Information                     HTML     71K 
12: R2          Consolidated Balance Sheets                         HTML    137K 
13: R3          Consolidated Balance Sheets (Parenthetical)         HTML     39K 
14: R4          Consolidated Statements of Operations (Unaudited)   HTML     88K 
15: R5          Consolidated Statements of Stockholders' Equity     HTML     42K 
16: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML    126K 
17: R7          Description of Business                             HTML     23K 
18: R8          Summary of Significant Accounting Policies          HTML     29K 
19: R9          Revenue                                             HTML     60K 
20: R10         Long-Term Obligations                               HTML     89K 
21: R11         Securitization Facility                             HTML     30K 
22: R12         Fair Value Measurements                             HTML     74K 
23: R13         Derivative Financial Instruments                    HTML     45K 
24: R14         Income Taxes                                        HTML     28K 
25: R15         Share-Based Compensation                            HTML     50K 
26: R16         Commitments and Contingencies                       HTML     50K 
27: R17         Covid-19                                            HTML     44K 
28: R18         Related Party Transactions                          HTML     26K 
29: R19         Segment Information                                 HTML    131K 
30: R20         Net Income Per Share                                HTML     60K 
31: R21         Summary of Significant Accounting Policies          HTML     37K 
                (Policies)                                                       
32: R22         Revenue (Tables)                                    HTML     45K 
33: R23         Long-Term Obligations (Tables)                      HTML     69K 
34: R24         Fair Value Measurements (Tables)                    HTML     70K 
35: R25         Derivative Financial Instruments (Tables)           HTML     33K 
36: R26         Segment Information (Tables)                        HTML    125K 
37: R27         Net Income Per Share (Tables)                       HTML     58K 
38: R28         Description of Business - Additional Information    HTML     20K 
                (Details)                                                        
39: R29         Revenue - Additional Information (Detail)           HTML     26K 
40: R30         Revenue - Schedule of Revenue by Payer Type as a    HTML     34K 
                Percentage of Revenue (Detail)                                   
41: R31         Acquisitions - Additional Information (Details)     HTML     24K 
42: R32         Acquisitions - Summary of Preliminary Purchase      HTML     21K 
                Price Allocations (Details)                                      
43: R33         Long-Term Obligations - Schedule of Long-Term       HTML     54K 
                Obligations and Notes Payable (Details)                          
44: R34         Long-Term Obligations - Schedule of Long-Term       HTML     26K 
                Obligations and Notes Payable (Parenthetical)                    
                (Details)                                                        
45: R35         Long-Term Obligations - Additional Information      HTML     82K 
                (Details)                                                        
46: R36         Securitization Facility - Additional Information    HTML     34K 
                (Details)                                                        
47: R37         Fair Value Measurements - Summary of Other Assets   HTML     36K 
                and Other Liabilities Measured at Fair Value                     
                (Details)                                                        
48: R38         Derivative Financial Instruments - Additional       HTML     49K 
                Information (Details)                                            
49: R39         Derivative Financial Instruments - Schedule of      HTML     26K 
                Gains from Derivatives (Details)                                 
50: R40         Income Taxes - Additional Information (Detail)      HTML     27K 
51: R41         Share-Based Compensation - Additional Information   HTML     66K 
                (Details)                                                        
52: R42         Commitments and Contingencies - Additional          HTML     59K 
                Information (Details)                                            
53: R43         Covid-19 - Additional Information (Detail)          HTML     64K 
54: R44         Related Party Transactions - Additional             HTML     26K 
                Information (Details)                                            
55: R45         Segment Information - Additional Information        HTML     23K 
                (Details)                                                        
56: R46         Segment Information - Summary of Segment            HTML     45K 
                Information (Details)                                            
57: R47         Segment Information - Summary of Segment            HTML     52K 
                Reconciliation (Details)                                         
58: R48         Net Income Per Share - Summary of Computation of    HTML     60K 
                Basic and Diluted Net Income Per Share (Detail)                  
61: XML         IDEA XML File -- Filing Summary                      XML    109K 
59: XML         XBRL Instance -- avah-20220402_htm                   XML   1.30M 
60: EXCEL       IDEA Workbook of Financial Reports                  XLSX     70K 
 6: EX-101.CAL  XBRL Calculations -- avah-20220402_cal               XML    181K 
 8: EX-101.DEF  XBRL Definitions -- avah-20220402_def                XML    537K 
10: EX-101.LAB  XBRL Labels -- avah-20220402_lab                     XML   1.17M 
 9: EX-101.PRE  XBRL Presentations -- avah-20220402_pre              XML    800K 
 7: EX-101.SCH  XBRL Schema -- avah-20220402                         XSD    162K 
62: JSON        XBRL Instance as JSON Data -- MetaLinks              349±   515K 
63: ZIP         XBRL Zipped Folder -- 0000950170-22-009347-xbrl      Zip    235K

‘EX-31.1’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Tony Strange, certify that:

I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2022 of Aveanna Healthcare Holdings Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 11, 2022	By:	/s/ *Tony Strange*
		Tony Strange
		Chief Executive Officer (Principal Executive Officer)

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed on:	5/11/22	8-K
For Period end:	4/2/22
		List all Filings

↑Top

Filing Submission 0000950170-22-009347 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)